...
首页> 外文期刊>Biomaterials >A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines.
【24h】

A high-throughput microparticle microarray platform for dendritic cell-targeting vaccines.

机译:用于树突细胞靶向疫苗的高通量微粒微阵列平台。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Immunogenomic approaches combined with advances in adjuvant immunology are guiding progress toward rational design of vaccines. Furthermore, drug delivery platforms (e.g., synthetic particles) are demonstrating promise for increasing vaccine efficacy. Currently there are scores of known antigenic epitopes and adjuvants, and numerous synthetic delivery systems accessible for formulation of vaccines for various applications. However, the lack of an efficient means to test immune cell responses to the abundant combinations available represents a significant blockade on the development of new vaccines. In order to overcome this barrier, we report fabrication of a new class of microarray consisting of antigen/adjuvant-loadable poly(D,L lactide-co-glycolide) microparticles (PLGA MPs), identified as a promising carrier for immunotherapeutics, which are co-localized with dendritic cells (DCs), key regulators of the immune system and prime targets for vaccines. The intention is to utilize this high-throughput platform to optimize particle-based vaccines designed to target DCs in vivo for immune system-related disorders, such as autoimmune diseases, cancer and infection. Fabrication of DC/MP arrays leverages the use of standard contact printing miniarraying equipment in conjunction with surface modification to achieve co-localization of particles/cells on isolated islands while providing background non-adhesive surfaces to prevent off-island cell migration. We optimized MP overspotting pin diameter, accounting for alignment error, to allow construction of large, high-fidelity arrays. Reproducible, quantitative delivery of as few as 16+/-2 MPs per spot was demonstrated and two-component MP dosing arrays were constructed, achieving MP delivery which was independent of formulation, with minimal cross-contamination. Furthermore, quantification of spotted, surface-adsorbed MP degradation was demonstrated, potentially useful for optimizing MP release properties. Finally, we demonstrate DC co-localization with PLGA MPs on isolated islands and that DCs do not migrate between islands for up to 24 h. Using this platform, we intend to analyze modulation of DC function by providing multi-parameter combinatorial cues in the form of proteins, peptides and other immuno-modulatory molecules encapsulated in or tethered on MPs. Critically, the miniaturization attained enables high-throughput investigation of rare cell populations by reducing the requirement for cells and reagents by many-fold, facilitating advances in personalized vaccines which target DCs in vivo.
机译:免疫基因组学方法与佐剂免疫学的进步相结合,正在指导疫苗合理设计的进展。此外,药物递送平台(例如,合成颗粒)显示出增加疫苗效力的希望。当前,存在数十种已知的抗原表位和佐剂,以及众多可用于配制疫苗用于各种应用的合成递送系统。但是,缺乏测试免疫细胞对丰富可用组合的反应的有效方法,这严重阻碍了新疫苗的开发。为了克服这一障碍,我们报告了由抗原/佐剂负载的聚(D,L丙交酯-共-乙交酯)微粒(PLGA MP)组成的新型微阵列的制造,这些微粒被确定为免疫治疗的有希望的载体,与树突状细胞(DC),免疫系统的关键调节剂和疫苗的主要靶标共定位。目的是利用该高通量平台优化针对体内DC的针对基于颗粒的疫苗,以针对免疫系统相关疾病,例如自身免疫性疾病,癌症和感染。 DC / MP阵列的制造利用标准接触印刷微型阵列设备的使用以及表面修饰,以实现颗粒/细胞在孤立岛上的共定位,同时提供背景非粘附性表面以防止离岛细胞迁移。我们优化了MP过度定位销的直径,解决了对准误差,从而可以构建大型的高保真阵列。证明了每个点可重复的定量递送少至16 +/- 2 MP,并构建了两组分MP定量给料阵列,实现了MP递送,而与制剂无关,交叉污染最小。此外,证明了斑点的,表面吸附的MP降解的定量,可能对优化MP的释放性能有用。最后,我们证明了DC与PLGA MP的共定位在孤立的岛上,并且DC在岛之间迁移的时间长达24小时。使用该平台,我们打算通过提供多参数组合线索来分析DC功能的调制,这些线索以蛋白质,肽和其他封装在或捆绑在MP上的免疫调节分子的形式出现。至关重要的是,通过将细胞和试剂的需求降低了许多倍,从而实现了针对体内DC的个性化疫苗的发展,实现的小型化能够对稀有细胞群体进行高通量研究。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号